Immediate Impact
1 from Science/Nature 52 standout
Citing Papers
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
2024 Standout
Liquid biopsy in cancer: current status, challenges and future prospects
2024 Standout
Works of Risheng Que being referenced
Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.
2022
Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Risheng Que | 428 | 207 | 443 | 383 | 45 | 922 | |
| Jean-Philippe Dalès | 406 | 156 | 393 | 530 | 46 | 1.0k | |
| Xin Liu | 276 | 455 | 262 | 382 | 54 | 1.0k | |
| Antonella Palazzo | 698 | 478 | 341 | 305 | 64 | 1.2k | |
| Xiaodong Tian | 461 | 163 | 384 | 506 | 72 | 1.1k | |
| Zhe Su | 306 | 165 | 335 | 299 | 41 | 828 | |
| Keizo Sugimachi | 390 | 242 | 252 | 351 | 26 | 890 | |
| Jianjun Han | 269 | 122 | 266 | 391 | 57 | 889 | |
| Hui Yang | 369 | 459 | 427 | 484 | 59 | 1.1k | |
| Wenhe Zhao | 209 | 101 | 314 | 380 | 44 | 850 | |
| Guoshuang Shen | 504 | 344 | 213 | 292 | 57 | 945 |
All Works
Login with ORCID to disown or claim papers
Loading papers...